- Ricquita Pollard
The development of more targeted means of treating cancer is vital. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of antibodies or T cells that recognize the peptide. If the peptide is from a protein found selectively on/in cancer cells, those antibodies or T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient.
TARP (T cell receptor gamma alternate reading frame protein) is a protein that is selectively expressed on the cells of about 95% of prostate cancers and about 50% of breast cancers. This invention concerns the identification of a combination of seven (7) immunogenic peptides within TARP and their use to create an anti-cancer immune response in patients. The vaccine includes two synthetic 9-mer TARP peptides covered by E-116-2003 and five additional 20-mer peptides overlapping by 10-mer and covering the entire 58-residue sequence of the TARP protein. Because the additional peptides are overlapping, they can stimulate both humoral and cellular killing responses. By introducing these seven peptides into a patient, an immune response against these cancer cells can be initiated by the peptides, resulting in treatment of the cancer.
NCI seeks licensees or co-development partners to commercialize this invention.
- Peptides can be used as vaccines to induce an immune response against cancer.
- Treatment of any cancer associated with increased or preferential expression of TARP.
- Specific diseases include breast cancer and prostate cancer.
- Targeted therapy decreases non-specific killing of healthy, essential cells, resulting in fewer non-specific side-effects and healthier patients
- Not restricted to tissue type
- Use of multiple peptides permits production of a more thorough complement of T cells against the antigen
Jay Berzofsky (NCI), Masaki Terabe (NCI), Lauren Wood (NCI), Brenda Roberson (NCI)
- Pre-clinical (in vivo)
Wood L, et al. [PMC5007958]
Epel M et al. [PMID 18446790]
Oh S et al. [PMID 15059918]
- U.S. Provisional: U.S. Provisional Patent Application Number 61/915,948, Filed 13 Dec 2013
- U.S. Provisional: U.S. Provisional Patent Application Number PCT/US2014/070144, Filed 12 Dec 2012
- U.S. Patent Filed: U.S. Patent Application Number 15/102,996, Filed 09 Jun 2016
- Foreign Filed: Canada - Patent Application 2932248, Filed 12 Dec 2014
- Foreign Filed: European - Patent Application 14831120.2, Filed 12 Dec 2014
- Foreign Filed: Japan - Patent Application 2016-538101, Filed 09 Jun 2016
- Foreign Filed: Australia - Patent Application 2014361788, Filed 09 Jun 2016